Asia-Pacific Continuous Bioprocessing Market to be Worth $181.1 Million by 2030
Meticulous Research– a
leading global market research company, published a research report
titled “Asia-Pacific Continuous Bioprocessing Market by
Product (Filtration, Chromatography, Centrifuges, Consumables), Application
(Commercial {Vaccines, Monoclonal Antibodies}, R&D), and End User
(Pharmaceuticals, Biotechnology, CROs) - Forecast to 2030”.
download
Free sample Report Here: https://www.meticulousresearch.com/download-sample-report/cp_id=5682?utm_source=blog&utm_medium=social+&utm_campaign=product&utm_content
04-03-2024
According
to this latest publication from Meticulous Research, the Asia-Pacific
continuous bioprocessing market is expected to grow at a CAGR of 28.9% from
2023 to reach $181.1 million by 2030. The growth of this market is attributed
to factors such as the emerging landscape of biopharmaceuticals in Asian
countries, rising manufacturing and research-related outsourcing of
biopharmaceuticals, expansions in CDMOs, developments in bioprocessing
technologies, and growing partnerships and collaborations among market players
for biopharma manufacturing. Furthermore, the shift towards bioprocessing 4.0
and the rising adoption of personalized medicines are expected to provide
significant market growth opportunities.
However,
the limitations of continuous bioprocessing may restrain the growth of this
market. Additionally, manufacturers’ hesitation to shift from batch
manufacturing to continuous manufacturing poses challenges to the market
players.
Key
Players:
The
key players operating in Asia-Pacific continuous bioprocessing market are 3M
Company (U.S.), Cytiva (U.S.), Thermo Fisher Scientific Inc. (U.S.), Merck KGaA
(Germany), Sartorius AG (Germany), Repligen Corporation (U.S.), Eppendorf AG
(Germany), Applikon Biotechnology (Netherlands), Pall Corporation (U.S.),
Solida Biotech GmBH (Germany), Electrolab Biotech Limited (U.K.), Biowest
(France), and Bionet (U.S.).
Asia-Pacific
Continuous Bioprocessing Market: Future Outlook
Asia-Pacific
continuous bioprocessing market is segmented by Product (Filtration Systems and
Consumables, Chromatography Systems and Consumables, Cell Culture Media,
Buffers, and Reagents, Incubators and Shakers, Bioreactors, Centrifuges,
Sterilizers, and Other Instruments and Consumables), Application (Commercial
Applications [Monoclonal Antibodies (mAbs) Production, Cell and Gene Therapy
Production, Vaccine Manufacturing, Plasma Fractionation, and Recombinant
Protein Production], R&D), End User (Pharmaceutical and Biotechnology
Companies, Contract Development and Manufacturing Organizations (CDMOS) and
Contract Research Organizations (CROS), and Academic and Research Institutes),
and Country. The study also evaluates industry competitors and analyzes the
market at the country level.
Speak to
analyst: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5682?utm_source=blog&utm_medium=social+&utm_campaign=product&utm_content=04-03-2024
In
2023, among the products, the
filtration systems and consumables segment is estimated to account for the
largest share of the market. Filtration is commonly used in biopharmaceutical
processing for separating components. It is used in various downstream
operations, such as clarification, filtration of intermediates, critical final
filling applications, or upstream processing for sterilizing-grade filtration
of cell culture media. The highest revenue share of this segment is attributed
to the recurring use of filtration at every step in bioprocessing and
technological advancements in filtration technologies.
In
2023, among the applications, the
commercial applications segment is estimated to account for the largest share
of the market. Growing initiatives supporting the adoption of
biopharmaceuticals, rising biopharmaceutical manufacturing outsourcing, and
accelerated developments in personalized therapies are likely to enhance the
demand for bioprocessing systems and consumables for the commercial
bioproduction of monoclonal antibodies (mAbs), vaccines, gene therapies, and
recombinant protein-based therapies; thereby drive the continuous bioprocessing
market for commercial application.
Download request sample
report here: https://www.meticulousresearch.com/request-sample-report/cp_id=5682?utm_source=blog&utm_medium=social+&utm_campaign=product&utm_content=04-03-2024
In
2023, among the end users, the
pharmaceutical and biotechnology companies segment is estimated to account for
the largest market share due to factors such as capacity expansions by
biopharmaceutical manufacturers and the extensive adoption of biopharmaceutical
processing equipment for bioproduction in the biopharmaceutical and
biotechnology sectors.
Geographic
Review:
This
research report provides a comprehensive analysis of the continuous
bioprocessing market in Asia-Pacific (China, India, Japan, Singapore, South
Korea, Australia, New Zealand, Indonesia, and Rest of Asia-Pacific). In 2023,
China is expected to account for the largest share of the Asia-Pacific
continuous bioprocessing market. The growing focus on the pharmaceutical and
biopharmaceutical industry, rising investment in biosimilars, and support
initiatives for CDMOs are the factors driving the market growth.
Contact
Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Comments
Post a Comment